Last reviewed · How we verify
NCT05056831
Multicomponent Physical Activity Intervention for the Reduction of Psychosocial Distress in Cancer Patients
NA trial testing Behavioral Intervention in Anxiety Disorder in 2 participants. Terminated before completion.
7 October 2024
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 2 |
| Start date | 21 June 2021 |
| Primary completion | 7 October 2024 |
| Estimated completion | 7 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Behavioral Intervention
- Best Practice
- Informational Intervention
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Anxiety Disorder — all drugs for Anxiety Disorder →
- Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →
- Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Anxiety Disorder or Hematopoietic and Lymphoid Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study adapts and assesses the effect of a multicomponent physical activity intervention in reducing psychosocial distress in cancer patients. This study aims to develop a program to help increase physical activity and reduce stress in cancer survivors who live in rural areas.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05056831
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Behavioral Intervention
Trials testing the same drug.
- NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer · NA · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians · NA · recruiting
- NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
- NCT06904391 — Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA · NA · recruiting
Other recruiting trials for Anxiety Disorder
Currently open trials in the same condition.
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT07221409 — Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment · NA · recruiting
- NCT07045818 — DLPFC and Sympathetic Reactivity in RPL With Anxiety · recruiting
- NCT05232032 — Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation · Phase 2 · recruiting
- NCT06333925 — Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study · NA · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05056831 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05056831.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing